Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Conditions
Interventions
Mepolizumab
Placebo
Locations
361
United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Dothan, Alabama, United States
GSK Investigational Site
Huntsville, Alabama, United States
GSK Investigational Site
Jasper, Alabama, United States
GSK Investigational Site
Sheffield, Alabama, United States
GSK Investigational Site
Chandler, Arizona, United States
Start Date
October 30, 2019
Primary Completion Date
August 8, 2024
Completion Date
August 8, 2024
Last Updated
August 15, 2025
NCT06712563
NCT06831994
NCT02755974
NCT05087641
NCT05050591
NCT05913765
Lead Sponsor
GlaxoSmithKline
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions